Treatment of Helicobacter pylori infection

BMJ

Volumn 320, Issue 7226, 2000, Pages 31-

  de Boer, Wink A ^a   Tytgat, Guido N J ^b  

^a ST ANNA HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT FAILURE; TREATMENT PLANNING; ULCER; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HELICOBACTER INFECTION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0033629462     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.320.7226.31     Document Type: Article

References (37)

1. Hopkins RJ, Girardi LS, Turney EA. Relationship between H pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-1252.
2. De Boer WA, Tytgat GNJ. The best therapy for Helicobacter pylori infection. Should efficacy or side effect profile determine our choice? Scand J Gastroenterol 1995; 30: 401-407.
3. Neil GA. Do ulcers burn out or burn on? Managing duodenal ulcer diathesis in the Helicobacter pylori era. Am J Gastroenterol 1997; 92: 387-392.
4. Penston JG. Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Ther 1996; 10: 469-486.
5. Soll AH. Consensus statement. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA 1996; 275: 622-629.
6. Van der Hulst RWM, Rauws EAJ, Koycu B, Keller JJ, Ten Kate FJW, Dankert J, etal. Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis 1997; 176: 196-200.
7. Wilhelmsen I. Quality of life and Helicobacter pylori eradication. Scand J Gastroenterol 1996; 31(suppl 221): 18-20.
8. De Boer WA, Tytgat GNJ. How to treat H pylori infection. Should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996; 8: 709-716.
9. Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996; 10: 139-145.
10. Bodger K, Daly MJ, Heatley RV. Clinical economics review: Helicobacter pylori associated peptic ulcer disease. Aliment Pharmacol Ther 1997; 11: 273-282.
11. Current European concepts in the management of Helicobacter pylori infection. the Maastricht consensus report. Gut 1997; 41: 8-13.
12. Van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6-19.
13. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 91: 246-257.
14. Kolkman JJ, Tan TG, Oudkerk Pool M, van Kleef WA, Geraedts AAM, Timmerman RJ, et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1123-1129.
15. Pare P, Romaozinho J, Bardhan KD, French PC, Roberts PM. Ranitidine bismuth citrate is more effective than omeprazole in the eradication of H pylori when co-prescribed with clarithromycin. Gastroenterology 1997; 112: A251.
16. Megraud F, Pichavant R, Palegry D, French PC, Roberts PM. Ranitidine bismuth citrate co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997; 41(suppl 1): A92.
17. Chiba N, Hunt RH. Bismuth, metronidazole and tetracycline and acid suppression in H pylori eradication: a meta-analysis. Gut 1996; 39(suppl 2): A36-A37.
18. Lerang F, Moum B, Ragnhildstveit E, Haug JB, Hauge T, Tolas P, et al. A comparison between omeprazole-based triple therapy and bismuth based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-year follow-up study. Am J Gastroenterol 1997; 92: 653-658.
19. Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY. How do clinicians practising in the US manage Helicobacter pylori related gastrointestinal diseases? Am J Gastroenterol 1998; 93: 553-556.
20. Buda A, Dal BON, Kusstatscher S, Grassi SA, Crestani B, Battaglia G, et al. Different lansoprazole dosages in H pylori eradication therapy: a prospective multicenter randomized study comparing 30 mg bid versus 15 mg bid. Gut 1997; 41(suppl1): A92.
21. Lamouliatte H, De Mascarel A, Megraud F, Samoyeau R. Double blind study comparing once daily versus twice daily dosage of PPI with amoxicillin-clarithromycin for H pylori cure. Gut 1997; 41(suppl 1): A93.
22. Huang JQ, Wilkinson JM, Chiba RH, Hunt RH. One week clarithromycin 500 mg bid is better than 250 mg bid for eradicating H pylori infection when combined with proton pump inhibitor and metronidazole or amoxicillin: a meta-analysis. Gut 1997; 41(suppl 1): A90-A91.
23. Thys JC, van Zwet AA, Thys WJ, Van der Wouden EJ, Kooy A. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997; 11: 305-309.
24. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 1997; 41: 735-739.
25. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253.
26. De Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Effect of acid suppression on efficacy of treatment for Helicobacter pylori. Lancet 1995; 345: 817-820.
27. Borody TJ, Shortis NP. Treatment of patients with failed eradication a personal view. In: Hunt RH,Tytgat GNJ,eds. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer Academic, 1996: 357-365.
28. Graham DY, De Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996; 91: 1072-1076.
29. De Koster E, De Reuck, Jonas C, Denis P, Otero J, Buset M, et al. French triple works fine in Brussels. Gastroenterology 1997; 112: A99.
30. Lee JM, Fallon C, Breslin NP, Hyde DK. H pylori eradication: quadruple therapy is effective in triple therapy failures. Gastroenterology 1997; 112: A195.
31. Huelin Benitez J, Jimenez Perez M, Duran Campos A, Espana P, Contreras J, De la Cruz Lombardo JM, et al. Quadruple therapy with omeprazole, tetracycline, metronidazole and bismuth as a second option after failure of a first eradication therapy. Gut 1998; 43(suppl 2): A86.
32. Borda F, Martinez A, Echarri A, Jimenez J, Rodriguez C, Jara C, et al. Clinical practice results of quadruple treatment in Helicobacter pylori eradication failure with OCA-7. Gut 1998; 43(suppl 2): A81.
33. Goddard AF, Logan RPH, Atherton JC, Hawkey CJ, Spiller RC. Maastricht consensus report regimen for second-line treatment of H pylori infection: how does it perform in practice? Gut 1997; 41(suppl 1): A96.
34. Peitz U, Nusch A, Sulliga M, Becker T, Stolte M, Borsch G. Second-line treatment of Helicobacter pylori infection. Gut 1997; 41(suppl 1): A104.
35. Katelaris PH, Jones DB. Testing for Helicobacter pylori infection after antibiotic treatment. Am J Gastroenterol 1997; 92: 1245-1247.
36. Kist M, Strobel S, Folsch UR, Kirchner T, Hahn EG, von Kleist DH, et al. Prospective assessment of the impact of primary antimicrobial resistance on cure rates of Helicobacter pylori infections. Gut 1997; 41(suppl 1): A90.
37. Buckley MJM, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-2115.